BioSpace News Archive

Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will make separate presentations at the World Vaccine Congress Europe 2022 in Barcelona, Spain on Thursday, October 13, 2022.

HUTCHMED Limited announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis who received 12 weeks of combination induction therapy with guselkumab and golimumab.

Passage Bio, Inc. today announced the appointment of William Chou, M.D. as chief executive officer (CEO) and a member of the board, effective immediately.

Nanoscope Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for the treatment of retinitis pigmentosa (RP) via intravitreal injection.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company plans to release its third quarter 2022 financial results after the close of the U.S. financial markets on November 3, 2022.

Neuspera® Medical today announced the first patient successfully implanted with the Nuvella™ system in its pivotal clinical trial (SANS-UUI).

Evonik has entered into a long-term supply agreement with Phathom Pharmaceuticals, a U.S. biopharmaceutical company focused on developing and commercializing new treatments for gastric acid-related diseases.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).

Ochre Bio, an innovator in chronic liver disease drug development, today announced the successful close of $30M in Series A financing.